ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
AIM ImmunoTech initiates dosing in intranasal Covid-19 drug study pharmaceutical-technology
March 10, 2021AIM ImmunoTech has dosed the first healthy participants in a Phase I clinical study of its Ampligen drug as a potential intranasal prophylaxis or early-stage treatment for Covid-19 and other respiratory viral diseases.
Pharma Sources Insight July 2025
